These observations would suggest that TKIs plus inhibitors of metabolic nutrient signaling within the p38MAPK-Smad3 pathway (e.g., TocrisetTM and SIS3) could be beneficial to CML patients (Supplementary Figure 2) (165). Here, SMAD3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.